Insmed Inc.
Insmed Retains Rights to Brensocatib as AstraZeneca Option Negotiations Fail
Summary
On June 12, 2024, Insmed Incorporated announced that AstraZeneca AB exercised its second and final option under the 2016 License Agreement to develop and commercialize brensocatib for COPD or asthma. However, after the negotiation period, no agreement was reached, and Insmed retains full rights to brensocatib in all indications except COPD or asthma. AstraZeneca has no further rights for brensocatib in any indication.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement